When looking for a place to grow a life sciences business over the long term, sometimes the biggest location isn't ...

Clean, humanized data and data systems are the crucial fuel for engines driving new AI capabilities and uses across the ...

The FDA's new FAQ on cell and gene therapy offers a roadmap for developers. Review key insights from the document, including ...

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski explain the importance of transparency and collaboration when encountering manufacturing speed bumps.

Profluent Bio’s Hilary Eaton is passionate about developing technology that tackles rare diseases on the genetic level, an issue that personally affects her and her family.

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

In this executive virtual roundtable (EVR) component, Usama Malik, CEO of Fore Biotherapeutics, discusses the challenges faced as a startup CEO trying to fill multiple positions during a red-hot ...

Local affiliates face significant time demands, often with very limited resources. These demands are perhaps most keenly felt in pharmacovigilance (PV). In many markets, requirements can include ...

Francois is chairman of the board at Acceleron Pharma. He is the former CEO of NPS Pharmaceuticals and serves on several other corporate and philanthropy boards.